Production & Manufacturing
Packaging & Labelling
Autopack to host biggest packaging machinery stand at PPMA Total 2025
Leading independent integrator of packaging lines Autopack will showcase a range of cutting-edge automated equipment at PPMA Total 2025, which takes place at Birmingham’s NEC from 23-25 September. The Hereford-based business will take its largest individual stand to date in what...
BioPharma
Bionova Scientific Opens US pDNA Development Facility
The 10,000 ft.² Woodlands site is located near Houston in Texas and is going to design, develop, and even manufacture research-grade plasmid DNA - pDNA materials in order to support the work of the CDMO within cell and gene...
News
The FDA PreCheck Program To Speed-Up US Drug Production
The US Food and Drug Administration announced on August 7, 2025, FDA PreCheck, which is a new program in order to strengthen the domestic pharmaceutical supply chain by way of increasing regulatory productivity along with facilitating the construction of...
News
Reshoring Amidst Tariff Cloud – Aurobindo Acquires Lannett
Aurobindo acquires Lannett – the US Drugmaker for $250 million thereby shoring up the Indian drugmaker's footprint in the US in the middle of the threats that the Trump administration plans so as to impose tariffs when it comes...
BioPharma
Canada-UK Partnership Integrates Bioreactor Technologies
In a recent move, an international initiative is going to transform biologics as well as drug manufacturing by way of AI-driven multi-platform integration. The AI-optimized BALANCE (Bioreactor automation for learning and adaptive networked control of experiments) platform is going...
News
Law to Decentralize Personalized Drug Manufacturing in UK
A legislation to decentralize personalized drug manufacturing in UK has been passed, enabling them to be prepared across facilities, which are closer to the patient.
This recent legislation, which has been passed, which is the Human Medicine Regulations 2025, goes on...
BioPharma
AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D
AstraZeneca announces $50 billion of investment in the United States by 2030, building on America’s global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.